Approval · Notice of Compliance 33844 · 2024
JAMP DIVALPROEX: Notice of Compliance 33844
Issued August 22, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33844
- Date
- August 22, 2024
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- EPIVAL (BGP Pharma ULC)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP DIVALPROEX | 02551144 | Approved |
| JAMP DIVALPROEX | 02551152 | Marketed |
| JAMP DIVALPROEX | 02551160 | Marketed |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB